Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1378670 | Bioorganic & Medicinal Chemistry Letters | 2006 | 4 Pages |
Abstract
Starting with the weak agonist indomethacin, a series of potent, selective CRTh2 (DP2) antagonists have been discovered as potential treatments for asthma, allergic rhinitis and other inflammatory diseases.
Graphical abstractThe discovery and optimisation of potent antagonists of the CRTh2 receptor is described culminating in the synthesis of 12, a novel, potent, selective and metabolically stable lead compound.Figure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Timothy N. Birkinshaw, Simon J. Teague, Claire Beech, Roger V. Bonnert, Stephen Hill, Anil Patel, Sara Reakes, Hitesh Sanganee, Iain G. Dougall, Tim T. Phillips, Sylvia Salter, Jerzy Schmidt, Elizabeth C. Arrowsmith, Juan J. Carrillo, Fiona M. Bell,